Aesynt Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Aesynt's estimated annual revenue is currently $29.2M per year.(i)
  • Aesynt's estimated revenue per employee is $270,000

Employee Data

  • Aesynt has 108 Employees.(i)
  • Aesynt grew their employee count by 0% last year.

Aesynt's People

NameTitleEmail/Phone
1
Director, Sales EnablementReveal Email/Phone
2
Technical Account ManagerReveal Email/Phone
3
Sr. Centralized Hardware EngineerReveal Email/Phone
4
Technical Solutions EngineerReveal Email/Phone
5
Sr. Control Software EngineerReveal Email/Phone
6
Interface EngineerReveal Email/Phone
7
Installation and Implementation EngineerReveal Email/Phone
8
Software Quality Assurance LeadReveal Email/Phone
9
Software Quality Assurance Engineer IIReveal Email/Phone
10
Field Service EngineerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$14.8M61-3%N/AN/A
#2
$14.1M5812%N/AN/A
#3
$468M12389%N/AN/A
#4
$9.7M452%N/AN/A
#5
$4M2162%N/AN/A
#6
$6.5M300%N/AN/A
#7
$14.8M6113%N/AN/A
#8
$62.1M2093%N/AN/A
#9
$8.4M3911%N/AN/A
#10
$33.5M1241%N/AN/A
Add Company

What Is Aesynt?

Aesynt is now part of Omnicell Inc. Stay up-to-date with company news and product information at https://lnkd.in/dRZxuex. At Aesynt, we’re leading the journey to perfect medication management by pioneering a new path— one that optimizes both labor and drug expenses across the enterprise for all forms of medications, allowing our healthcare partners to dramatically reduce costs and improve patient safety. Grounded by our strategic vision, we enable our healthcare partners to integrate, automate and manage medication preparation and delivery system-wide through the industry’s most comprehensive medication management portfolio.

keywords:N/A

N/A

Total Funding

108

Number of Employees

$29.2M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$20.2M1245%N/A
#2
$63.7M1649%N/A
#3
$15M1676%N/A
#4
$78.8M20321%N/A
#5
$65.6M3503%N/A